结直肠癌改良三药cmFOLFOXIRI方案临床应用中国专家共识

Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan,oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer

结直肠癌是我国发病率第2位的常见恶性肿瘤。由氟尿嘧啶、奥沙利铂和伊立替康联合的FOLFOXIRI三药方案是一种治疗结直肠癌的高强度化疗方案,具有疗效显著但毒性较大等特点。为了推动我国临床工作者对FOLFOXIRI方案的规范化和合理化应用,由中国南方肿瘤临床研究协会结直肠癌专业委员会牵头制定了《结直肠癌改良三药cmFOLFOXIRI方案临床应用中国专家共识》。本共识分别针对结直肠癌姑息治疗、转化治疗和新辅助治疗,对FOLFOXIRI方案的临床应用进行推荐,并基于中国人群特点、3种化疗药物机制以及既往研究数据,首次提出了中国版改良FOLFOXIRI(Chinese modified FOLFOXIRI,cmFOLFOXIRI)的剂量用法和相关不良反应的管理,旨在进一步提高我国结直肠癌治疗水平,使更多患者获益。

Colorectal cancer is the second most common malignant tumor in China.The FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy regimen.However,the original regimen is poorly tolerated in Chinese patients.In order to promote the standardized and rational application of FOLFOXIRI regimen by clinicians in China,"Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan,Oxaliplatin,and Continuous Infusional 5-Fluorouracil/Leucovorin for Colorectal Cancer"was formulated by the Committee of Colorectal Cancer in Chinese Southwest Oncology Group.Based on the mechanism underlying the combined three drugs and toxicity profile,the dosage of Chinese modified FOLFOXIRI(cmFOLFOXIRI)regimen and the management of related adverse reactions is proposed.This consensus recommended that the FOLFOXIRI regimen be used in neoadjuvant,conversion,and palliative therapy for colorectal cancer under specific conditions.This consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer,in order to bring benefits to CRC patients and improve the treatment efficacy.